We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) closed at $559.44 in the latest trading session, marking a +1.95% move from the prior day. This move outpaced the S&P 500's daily gain of 1.62%. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 12.91%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had lost 6.53% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 4.54%.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $4.95 per share, which would represent a year-over-year decline of 31.72%. Our most recent consensus estimate is calling for quarterly revenue of $10.57 billion, down 10.58% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $23.72 per share and revenue of $45.34 billion, which would represent changes of +2.07% and +0.95%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.47% higher. Thermo Fisher Scientific currently has a Zacks Rank of #2 (Buy).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 23.14. This represents a discount compared to its industry's average Forward P/E of 25.9.
It is also worth noting that TMO currently has a PEG ratio of 1.85. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.24 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TMO in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
Thermo Fisher Scientific (TMO - Free Report) closed at $559.44 in the latest trading session, marking a +1.95% move from the prior day. This move outpaced the S&P 500's daily gain of 1.62%. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 12.91%.
Coming into today, shares of the maker of scientific instrument and laboratory supplies had lost 6.53% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 4.54%.
Thermo Fisher Scientific will be looking to display strength as it nears its next earnings release. On that day, Thermo Fisher Scientific is projected to report earnings of $4.95 per share, which would represent a year-over-year decline of 31.72%. Our most recent consensus estimate is calling for quarterly revenue of $10.57 billion, down 10.58% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $23.72 per share and revenue of $45.34 billion, which would represent changes of +2.07% and +0.95%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Thermo Fisher Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.47% higher. Thermo Fisher Scientific currently has a Zacks Rank of #2 (Buy).
Investors should also note Thermo Fisher Scientific's current valuation metrics, including its Forward P/E ratio of 23.14. This represents a discount compared to its industry's average Forward P/E of 25.9.
It is also worth noting that TMO currently has a PEG ratio of 1.85. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments industry currently had an average PEG ratio of 2.24 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TMO in the coming trading sessions, be sure to utilize Zacks.com.